1
Syed M Waheed
Bhatnagar Rakesh, Waheed Syed Mohsin, Chauhan Vibha: High level constitutive production of anthrax protective antigen. Bhatnagar Rakesh, Waheed Syed Mohsin, Chauhan Vibha, GUPTA Bhartee, May 15, 2003: WO/2003/040179

The present invention relates to a process for preparing anthrax protective antigen protein from E.coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E.coli. The steps of the process ...


2

3
Bhatnagar Rakesh, Gupta Pankaj, Batra Smriti, Chauhan Vibha, Singh Aparna, Ahuja Nidhi, Kumar Praveen: A process for the preparation of a non-toxic anthrax vaccine. Bhatnagar Rakesh, August 20, 2008: EP1958960-A2

Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B. anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF or ...


4
Bhatnagar Rakesh, Waheed Syed Moshin, Chauhan Vibha: High level constitutive production of anthrax protective antigen. Bhatnagar Rakesh, Waheed Syed Moshin, Chauhan Vibha, August 4, 2004: EP1442052-A1

The present invention relates to a process for preparing anthrax protective antigen protein from E.coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E.coli. The steps of the process ...


5
Bhatnagar Rakesh, Gupta Pankaj, Batra Smriti, Chauhan Vibha, Singh Aparna, Ahuja Nidhi, Kumar Praveen: A process for the preparation of a non-toxic anthrax vaccine. Bhatnagar Rakesh, September 8, 2004: EP1453534-A1

Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B.anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF or ...


6
Bhatnagar Rakesh, Gupta Pankaj, Batra Smriti, Chauhan Vibha, Singh Aparna, Ahuja Nidhi, Kumar Praveen: A process for the preparation of a non-toxic anthrax vaccine. Bhatnagar Rakesh, Gupta Pankaj, Batra Smriti, Chauhan Vibha, Singh Aparna, Ahuja Nidhi, Kumar Praveen, ANAND Pravin, June 12, 2003: WO/2003/048390

Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B.anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF or ...


7
BHATNAGAR RAKESH: Bispecific monoclonal antibody capable of cross reacting with lethal factor (LF) and edema factor (LF), and neutralizing edema toxin (LF) as well as lethal toxin (LF) of bacillus anthracis. BHATNAGAR RAKESH, Mehta Ramesh Kumar, September 29, 2011: WO/2011/117886

The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of B. anthracis. It also relates to process for preparation of said mAb, and to pharmaceuti ...


8
Joshi Mohan Chandra, Sharma Animesh, Birah Ajanta, Gupta Gorakh Prasad, Banerjee Nirupama, Bhatnagar Rakesh: Insecticidal xngroel protein of xenorhabdus nematophila. Joshi Mohan Chandra, Sharma Animesh, Birah Ajanta, Gupta Gorakh Prasad, Banerjee Nirupama, Bhatnagar Rakesh, SUBRAMANIAM Hariharan, November 27, 2008: WO/2008/142707

The present invention relates to a novel insecticidal protein named XnGroEL isolated and purified from Xenorhabdus nematophila having GENE BANK ACCESSION No. AY18449. The process for the purification of novel insecticidal protein named XnGroEL is also disclosed. The invention also relates to the pro ...


9
Bhatnagar Rakesh, Midha Shuchi: Dna vaccine against anthrax. Bhatnagar Rakesh, Midha Shuchi, SUBRAMANIAM Hariharan, May 22, 2009: WO/2009/063507

The present invention relates to development of a DNA vaccine against anthrax using the protease-cleaved fragment of protective antigen. This fragment is operably linked to gene targeting cassette, either on N-terminal as a peptide leader or on C-terminal as a membrane anchoring tag or both. The gen ...


10
Kaur Manpreet, Rai Anant, Bhatnagar Rakesh: Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof. Kaur Manpreet, Rai Anant, Bhatnagar Rakesh, Mehta Ramesh Kumar Et Al, December 23, 2009: WO/2009/153801

A pharmaceutical composition of vaccine against rabies, which comprises of DNA vaccine based on glycoprotein gene of rabies virus conjugated to LAMP-1 signal sequence at the C-terminus, and an adjuvant; and method of its preparation thereof.



Click the thumbnails below to visualize the patent trend.